Rangering i aksjer
#21732
MDxHealth S.A. is a commercial-stage precision diagnostics company that... MDxHealth S.A. is a commercial-stage precision diagnostics company that delivers urological solutions across the United States, the Netherlands, Belgium, Spain, Poland, Italy, the rest of the European Union, and other international markets. They offer innovative genomic testing solutions for prostate cancer, notably the non-invasive SelectMDx urine test and the epigenetic ConfirmMDx test. These advanced tools assist physicians in identifying clinically significant prostate cancer, thus minimizing the need for invasive procedures and their associated complications. Founded in 2003 as OncoMethylome Sciences SA, the company adopted its current name, MDxHealth SA, in October 2010 and is headquartered in Herstal, Belgium.
Aksjekurs
$3.58
Sist synkronisert: 2023-12-15
Handel MDxHealth S.A. (MDXH)
Pris MDXH pris med markedsverdi på B
Markedsverdi av MDxHealth S.A.(MDXH)
Markedsverdi: $101.57M
Per August 2026 har MDxHealth S.A. en markedsverdi på $101.57M. Dette gjør MDxHealth S.A. til det 21732nd mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for MDxHealth S.A. fra 2006 til 2026
MDXH sammenlignet med topp 5 mest populære stocks
| Pris på MDXH |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.211T
|
+5,130,713.72%
|
|
|
|
|
$4.547T
|
+4,476,364.28%
|
|
|
|
|
$4.162T
|
+4,098,034.15%
|
|
|
|
|
$3.593T
|
+3,537,154.86%
|
|
|
|
|
$2.793T
|
+2,749,583.54%
|
